
GIVLAARI contains the active ingredient givosiran in its sodium form, which is a small interfering RNA (siRNA) targeting aminolevulinate synthase 1. It is designed to be delivered to hepatocytes using a ligand with three N-acetylgalactosamine residues. The drug is available as a sterile, preservative-free solution for subcutaneous injection, with each vial containing 189 mg of givosiran. Key inactive ingredients include water for injection, and sodium hydroxide or phosphoric acid may be used for pH adjustment.